Navigation Links
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
Date:8/6/2014

WORCESTER, Mass. and TORONTO, Aug. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer.  The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival.  The compound is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.

The publication, entitled, "AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction," appears in the peer-reviewed journal Cancer Immunology, Immunotherapy, a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy (online publication July 23, 2014).  While a prior study showed that AE37-immunized patients had better overall and disease-free survival as a group than would be expected from their disease status, the current study shows that patients with the strongest immunological response did the best.  In particular, both the presence of AE37-induced T cells in peripheral blood as well as a robust delayed type hypersensitivity (DTH) response elicited by AE37 correlated significantly with overall survival.  The authors point out the importance of CD4+ T cells in developing a good DTH response.  AE37 was developed using the Antigen Express Ii-Key technology platform that ensures robust, specific CD4+ T cell activation.

The current report expands upon prior studies on the results of a Phase I trial of AE37 in patients with prostate cancer.  AE37 is also the subject of a controlled, randomized Phase II trial t
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
2. Generex Announces Selection of Antigen Express Technology for Keynote Presentation at 2014 TIDES Conference
3. Generex/Antigen Express Announce Database Lock of AE37 Breast Cancer Vaccine Trial
4. Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
5. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
6. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
7. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
10. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
11. Generex Secures Commitments for $3.6M Capital Raise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... NY (PRWEB) May 28, 2015 Whitehouse ... and enhanced its long term partnership with PTI Inspection ... together to provide clients with custom-tailored method development ... art instruments currently available. The agreement includes a more ... employees across organizational lines. This enables a more ...
(Date:5/28/2015)... MA (PRWEB) May 28, 2015 ... located in Basel, Switzerland, and the Alliance ... a Cambridge, Massachusetts-based non-profit organization operating in ... a global system to enhance quality, safety, ... development and health research, are pleased to ...
(Date:5/27/2015)... Muncie, IN (PRWEB) May 27, 2015 The ... public to join in celebrating National Model Aviation Day. The ... Aviation Day was created to celebrate the model aviation hobby ... AMA encourages all of its approximately 2,350 chartered clubs to ... hosting an event in their communities. There will also be ...
(Date:5/27/2015)... 2015 Empowering biomedical researchers with ... Cubresa Inc. today announced its MR Compatible Small ... PET Scanner uses silicon photomultiplier detector technology, so ... machines from manufacturers like Bruker and Agilent,” said ... Canada. “This enables simultaneous PET and MRI data ...
Breaking Biology Technology:Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3Cubresa Launches Simultaneous PET/MRI Technology 2
... Sept. 23 Spherix Incorporated (Nasdaq: SPEX ), an ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, ... on November 17, 2009, at 9:00 a.m. Eastern time, at the ... , The items of business are: , , ...
... , SAN FRANCISCO, September 23 ... patient has been enrolled in the,Israeli MGuard(TM) Registry. MGuard(TM) ... Cath Lab, managed by Dr. Yitzhak,Herz, the principal investigator ... The Israeli MGuard Registry will enroll 100 ...
... , , RESEARCH TRIANGLE ... CRO, announced a partnership with Max Healthcare to open a Phase ... India. This proof of concept unit will allow Pharmaceutical, Biotech & ... development process across multiple therapeutic areas quickly and with the highest ...
Cached Biology Technology:Spherix Incorporated Announces Annual Shareholders Meeting Date 2Spherix Incorporated Announces Annual Shareholders Meeting Date 3InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 3Max Neeman International to Open Phase I/IIa Unit 2
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/14/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has ... in Smart Mobile Devices " report to their ... a watershed year for fingerprint sensors in smartphones and ... gave fingerprint sensors a raison d,etre in the mobile ... a must-have feature in flagship smartphones. The ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... attend the 20th EORTCNCIAACR Symposium on "Molecular Targets ... Geneva] from Tuesday 21 October-Friday 24 October. ... booking accommodation via the official local agent if ... by the European Organisation for the Research and ...
... have found that a gene variant known to raise the ... role in white American children, but not in African American ... in the developed world, asthma is a complex disease in ... each other and with environmental influences to produce its effects. ...
... FAIRFAX, Va.ATTRACTthe first major national trial of a ... use of clot-dissolving drugs in combination with clot ... with DVT (the formation of a blood clot ... complication of DVT, causes permanent damage to the ...
Cached Biology News:Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2More findings on gene involved in childhood asthma 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 3
... Antigen sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 ... our corresponding peptide and ... 5 I-labelled peptide, ... (H-1470) and ([ 1 ...
... breakthrough in accurate, small-volume bulk dispensing. Dispensing precise ... 1 has unique advantages not found in any ... needs re-calibration as do other 1mL dispensers. ... Display , Graphical Row Selection , 96-,384- and ...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
... SYBR Green II RNA gel stain ... that has bright fluorescence when bound to RNA ... for use with either formaldehyde/agarose or polyacrylamide gels ... µL stains 50 minigels. A 1 mL unit ...
Biology Products: